{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:08:26Z","timestamp":1792080506669,"version":"4.4.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or other bleeding), death or study end (December 2018; in Germany, December 2017). Crude incidence rates of each outcome per 100 person-years were computed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 44 737 rivaroxaban and 45 842 vitamin K antagonist patients were enrolled, mean age, 59.9\u201363.8 years. Incidence rates were similar between rivaroxaban and vitamin K antagonist users with some exceptions, including higher incidence rates for gastrointestinal bleeding in rivaroxaban users than in vitamin K antagonist users. Among rivaroxaban users, mortality and bleeding risk generally increased with age, renal impairment and diabetes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study provides further data from routine clinical practice that broadly support safety profile of rivaroxaban for VTE indication and complement findings from previous randomized clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0298596","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:34:23Z","timestamp":1709836463000},"page":"e0298596","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-6306","authenticated-orcid":true,"given":"Ana","family":"Ruig\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron M. C.","family":"Herings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1882-4748","authenticated-orcid":true,"given":"Elisabeth","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Swart-Polinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Balabanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiliana","family":"Suzart-Woischnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alberto","family":"Garc\u00eda Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"4","key":"pone.0298596.ref001","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"AT Cohen","year":"2007","journal-title":"Thromb Haemost"},{"key":"pone.0298596.ref002","first-page":"107","article-title":"Risk factors for venous thromboembolism","author":"FA Anderson","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"pone.0298596.ref003","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).","volume":"41","author":"SV Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"pone.0298596.ref004","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmjqs-2012-001748","article-title":"The global burden of unsafe medical care: analytic modelling of observational studies","volume":"22","author":"AK Jha","year":"2013","journal-title":"BMJ Qual Saf"},{"key":"pone.0298596.ref005","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"F Khan","year":"2019","journal-title":"BMJ"},{"issue":"19","key":"pone.0298596.ref006","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"TL Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"pone.0298596.ref007","author":"AG Bayer","year":"2018","journal-title":"Summary of Product Characteristics, Xarelto."},{"key":"pone.0298596.ref008","author":"Janssen Pharmaceuticals, Inc","year":"2020","journal-title":"Prescribing Information, XARELTO\u00ae."},{"issue":"1","key":"pone.0298596.ref009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.","volume":"11","author":"MH Prins","year":"2013","journal-title":"Thromb J"},{"issue":"11","key":"pone.0298596.ref010","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/14740338.2020.1798928","article-title":"Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.","volume":"19","author":"LA Garcia-Rodriguez","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"26","key":"pone.0298596.ref011","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0298596.ref012","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Einstein-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0298596.ref013","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"DE Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"pone.0298596.ref014","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"17","key":"pone.0298596.ref015","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.","volume":"18","author":"BA Hutten","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0298596.ref016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4580","article-title":"Ascertainment and validation of major bleeding events in a primary care database.","volume":"28","author":"A Ruig\u00f3mez","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pone.0298596.ref017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.5146","article-title":"Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network.","volume":"30","author":"A Ruig\u00f3mez","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"pone.0298596.ref018","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"J Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"issue":"11","key":"pone.0298596.ref019","doi-asserted-by":"crossref","first-page":"e038102","DOI":"10.1136\/bmjopen-2020-038102","article-title":"Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study","volume":"10","author":"A Evans","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"pone.0298596.ref020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/rth2.12489","article-title":"Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies","volume":"5","author":"S Haas","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"pone.0298596.ref021","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1160\/TH17-03-0210","article-title":"Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism","volume":"117","author":"CI Coleman","year":"2017","journal-title":"Thromb Haemost"},{"key":"pone.0298596.ref022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.thromres.2018.05.031","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study","volume":"168","author":"CI Coleman","year":"2018","journal-title":"Thromb Res"},{"issue":"2","key":"pone.0298596.ref023","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejh.13185","article-title":"Comparative risk of major bleeding with rivaroxaban and warfarin: population-based cohort study of unprovoked venous thromboembolism","volume":"102","author":"CG Kohn","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"pone.0298596.ref024","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1160\/TH16-10-0745","article-title":"Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study","volume":"117","author":"C Sindet-Pedersen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"pone.0298596.ref025","first-page":"472","article-title":"Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)","volume":"116","author":"N Kucher","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"pone.0298596.ref026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"IL Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"pone.0298596.ref027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review.","volume":"40","author":"S Ballestri","year":"2023","journal-title":"Adv Ther."},{"key":"pone.0298596.ref028","first-page":"315","article-title":"Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.","author":"N Wallvik","year":"2020","journal-title":"J Thromb Thrombolysis."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:34:41Z","timestamp":1709836481000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298596"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298596","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}